Vinpocetine: An Unapproved Drug Sold as a Dietary Supplement

Mayo Clinic Proceedings

Volumn 90, Issue 10, 2015, Pages 1455-

  Cohen, Pieter A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VINPOCETINE; ANTIHYPERTENSIVE AGENT; NOOTROPIC AGENT; VINCA ALKALOID;

CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG CONTROL; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPOTENSION; LETTER; SIDE EFFECT; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; DIETARY SUPPLEMENTS; DRUG APPROVAL; HUMANS; NOOTROPIC AGENTS; UNITED STATES; VINCA ALKALOIDS;

EID: 84943654963     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.07.008     Document Type: Letter

References (5)

1. D. Bereczki, and I. Fekete Vinpocetine for acute ischaemic stroke Cochrane Database Syst Rev 1 2008 CD000480
2. National Toxicology Program. Chemical information review document for vinpocetine [CAS No. 42971-09-5]. http://ntp.niehs.nih.gov/ntp/htdocs/chem-background/exsumpdf/vinpocetine091613-508.pdf. Published September 2013. Accessed August 10, 2015.
3. Tanner J. 75-Day Premarket Notification for New Dietary Ingredients [vinpocetine]. US Food and Drug Administration website. http://www.fda.gov/ohrms/dockets/dockets/95s0316/rpt0012-01.pdf. Published August 29, 1997. Accessed August 10, 2015.
4. Natural Medicines Comprehensive Database. http://www.naturaldatabase.com. Accessed August 10, 2015.
5. Avula B, Chittiboyina A, Sagi S, Wang Y-H, Wang M, Khan IA, Cohen PA. Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States: drug testing and analysis. Drug Testing Analysis. doi: 10.1002/dta.1853.